Possibly, the effects of anti-inflammatory agents on anemia may be ‘dose-dependent’, implying that more intensified treatment with anti-inflammatory agents is associated with a slower decline in Hb levels and a greater decrease in transfusion requirements. The gene discussed is GSTM1; the disease is anemia.